CEO Interview: Jinok Ko of Ingenium Therapeutics

CEO Interview: Jinok Ko of Ingenium Therapeutics

Acute myeloid leukemia treatment approved for therapeutic use

Acute myeloid leukemia treatment approved for therapeutic use

Oct 18, 2024

In this interview, we had the pleasure of speaking with Jinok Ko, CEO of Ingenium Therapeutics, about cell therapies and acute myeloid leukemia treatments. We covered a wide range of topics, from his journey in founding a biotech company to his experience in out-licensing deals.

One particularly insightful discussion was about the difference between treatment-use approval and clinical trial approval for cell therapies, a topic that often causes confusion. He also shared valuable insights into the real-world application of these therapies.

We hope this interview provides you with useful and informative insights, and we appreciate your continued interest and support for Ingenium Therapeutics' future innovations.

Thank you for watching!

Back to News

Subscribe

By subscribing, you agree to our Privacy Policy.

한국어

|

EN

© 2025 Laplace Partners

Subscribe

By subscribing, you agree to our Privacy Policy.

한국어

|

EN

© 2025 Laplace Partners

Subscribe

By subscribing, you agree to our Privacy Policy.

한국어

|

EN

© 2025 Laplace Partners